Retatrutide 10mg
10mgA next-generation triple receptor agonist (GIP, GLP-1, and glucagon) studied in the metabolic and body-composition literature.
Overview
Retatrutide is a synthetic peptide that simultaneously activates three metabolic receptors - GIP, GLP-1, and glucagon - making it one of the most advanced multi-agonists in current metabolic research.
This product is supplied as 10mg of lyophilised powder for laboratory reconstitution and research use only.
Mechanism of action
By acting on GLP-1 and GIP receptors, retatrutide influences insulin secretion, appetite signalling, and gastric emptying, while glucagon-receptor activity adds an energy-expenditure component.
This triple mechanism is studied for its combined effect on glucose regulation and body composition in model systems.
Research highlights
Retatrutide has been the subject of prominent clinical research reporting substantial effects on body weight and metabolic markers among multi-agonist peptides.
Its unique triple-receptor profile makes it a key reference compound in metabolic pharmacology research.
Reference dosing
Research protocols typically use once-weekly subcutaneous injections with gradual titration over several weeks to improve tolerability. This reflects published research protocols only.
Storage & handling
Store lyophilised vials refrigerated at 2-8C, protected from light. Keep reconstituted solution refrigerated and use per protocol.
Specifications
| Contents | Retatrutide 10mg |
| Form | Lyophilised powder |
| Presentation | Single vial |
| Purity | >=99% (HPLC) |
| Reconstitution | Bacteriostatic water (not included) |
Frequently asked questions
What makes Retatrutide unique?
It is a triple agonist acting on GIP, GLP-1, and glucagon receptors simultaneously, unlike single- or dual-agonist peptides.
Is Retatrutide for human use?
No. It is supplied strictly as a research reference material for laboratory metabolic studies.